• Organizations: Novaliq
Harrow purchases US, Canadian commercial rights to Novaliq's VEVYE
Products

Harrow purchases US, Canadian commercial rights to Novaliq's VEVYE

Newly-FDA-approved product is the first and only cyclosporine water- and preservative-free solution indicated for DED treatment.
FDA approves Novaliq's VEVYE for DED
Products

FDA approves Novaliq's VEVYE for DED

Approval is the first and only for a cyclosporine solution indicated for the treatment of DED, with an efficacy demonstrated over 4 weeks.
Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED
Products

Bausch + Lomb and Novaliq receive FDA approval for MIEBO to treat DED

Formerly known as NOV03, the ophthalmic solution is now the first and only approved DED treatment directly targeting tear evaporation.
Bausch + Lomb, Novaliq release second phase 3 data for NOV03
Pipeline

Bausch + Lomb, Novaliq release second phase 3 data for NOV03

Results from MOJAVE study support potential for treating DED associated with MGD.
Consider it accepted — Weekly Glance
Archives

Consider it accepted — Weekly Glance

Novaliq has a major update on its new dry eye treatment.
Are there any new treatments for dry eye? — Weekly Glance
Archives

Are there any new treatments for dry eye? — Weekly Glance

An eye drop to treat MGD is on the horizon. — Weekly Glance
Archives

An eye drop to treat MGD is on the horizon. — Weekly Glance

Bausch + Lomb and Novaliq just submitted an NDA for NOV03, an eye drop that treats the signs and symptoms of dry eye disease associated with meibomian gland dysfunction (MGD).